Xeris Biopharma Holdings, Inc. Income Statement
XERS / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Xeris Biopharma Holdings, Inc. reported $292M in revenue and $554,000 in net income for FY2025. Revenue has grown at a 70.2% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $49.6M | $49.6M | $20.4M |
| SG&A Expense | $182.4M | $163.5M | $146.1M | $125.7M | $125.7M | $73.7M |
| R&D Expense | $31.2M | $25.6M | $22.3M | $25.2M | $25.2M | $20.9M |
| Operating Income | $24.9M | -$33.6M | -$44.0M | -$115.2M | -$115.2M | -$83.5M |
| Interest Expense | - | - | $26.6M | $7.2M | $7.2M | $10.7M |
| Income Tax | $0 | -$2.3M | -$1.2M | $0 | $0 | -$110.0K |
| Net Income | $554.0K | -$54.8M | -$62.3M | -$122.7M | -$122.7M | -$91.1M |
| EPS (Basic) | -$0.45 | -$0.70 | -$1.55 | -$1.55 | - | - |
| EPS (Diluted) | -$0.45 | -$0.70 | -$1.55 | -$1.55 | -$2.14 | - |
| Shares Outstanding | 149.4M | 138.1M | 136.3M | 124.9M | 42.6M | 42.6M |
| Operating Margin | 8.5% | -16.6% | -26.9% | -232.2% | -232.2% | - |
| Profit Margin | 0.2% | -27.0% | -38.0% | -247.5% | -247.5% | - |